NCT03866382 2026-03-18
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
140 trialsNCT05691465 2026-03-18
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07111507 2026-03-17
A Study of Tarlatamab for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07332000 2026-03-17
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06096870 2026-03-16
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05616650 2026-03-13
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07025369 2026-03-13
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Mayo Clinic
Phase 2 Recruiting
NCT07335796 2026-03-13
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05361798 2026-03-12
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06437574 2026-03-11
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT06216249 2026-03-10
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06330805 2026-03-09
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06957691 2026-03-09
Fezo-ADT
Brigham and Women's Hospital
Phase 2 Recruiting
NCT07451795 2026-03-05
SHARP
Fudan University
Phase 2 Recruiting
NCT06632977 2026-03-04
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT06675357 2026-03-04
Using FAPI PET/MRI to Evaluate Prostate Cancer
University of Wisconsin, Madison
Phase 2 Recruiting
NCT07005154 2026-03-03
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
Phase 2 Recruiting
NCT07072728 2026-03-03
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
Phase 2 Recruiting
NCT07230106 2026-03-03
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT07047118 2026-03-02
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Recruiting
NCT06395753 2026-02-27
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
Debiopharm International SA
Phase 2 Recruiting
NCT07247175 2026-02-25
The Impact of Force Feedback in the dV5 Robotic Surgical System on Learning Curve and Safety in Robot-Assisted Radical Prostatectomy - A Prospective, Single-Center, Investigator-Initiated Clinical Trial
Samsung Medical Center
Phase 2 Recruiting
NCT07285057 2026-02-23
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT04337580 2026-02-20
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT06526299 2026-02-20
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Phase 2 Recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06616597 2026-02-19
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03933670 2026-02-18
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
University of California, San Francisco
Phase 2 Recruiting
NCT06990542 2026-02-17
RadTARGET
University of California, San Diego
Phase 2 Recruiting
NCT06842498 2026-02-11
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Kyntra Bio
Phase 2 Recruiting
NCT04879940 2026-02-05
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06591819 2026-02-05
Hypofractionated WPPT With HDR Boost
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT06972875 2026-02-05
FLASH
University of Vermont
Phase 2 Recruiting
NCT07001241 2026-02-05
Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
University of Colorado, Denver
Phase 2 Recruiting
NCT03824652 2026-02-04
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT07202247 2026-02-04
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT05534646 2026-02-02
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT06172478 2026-01-28
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 2 Recruiting
NCT06397703 2026-01-28
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NYU Langone Health
Phase 2 Recruiting
NCT07073794 2026-01-28
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06111781 2026-01-27
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Yale University
Phase 2 Recruiting
NCT05498272 2026-01-23
NePtune
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05038332 2026-01-16
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT05053152 2026-01-14
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Recruiting